ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 114 filers reported holding ARBUTUS BIOPHARMA CORP in Q4 2022. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $61,000 | +24.5% | 31,900 | +155.2% | 0.00% | – |
Q4 2021 | $49,000 | -92.2% | 12,500 | -91.4% | 0.00% | -100.0% |
Q3 2021 | $626,000 | +1390.5% | 145,800 | +1046.3% | 0.01% | +500.0% |
Q1 2021 | $42,000 | -94.6% | 12,719 | -89.8% | 0.00% | -98.6% |
Q3 2017 | $775,000 | – | 125,000 | – | 0.07% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Whitefort Capital Management, LP | 11,895,477 | $24,147,818 | 12.66% |
Two Seas Capital LP | 8,280,818 | $16,810,061 | 3.38% |
FourWorld Capital Management LLC | 1,341,907 | $2,724,071 | 0.51% |
Tejara Capital Ltd | 180,077 | $365,556 | 0.21% |
Woodline Partners LP | 4,719,903 | $9,581,403 | 0.11% |
Hudson Bay Capital Management LP | 8,299,808 | $16,848,610 | 0.07% |
Kepos Capital LP | 155,691 | $316 | 0.06% |
Virtus ETF Advisers LLC | 40,040 | $81,281 | 0.05% |
Centiva Capital, LP | 1,071,705 | $2,175,561 | 0.05% |
Kades & Cheifetz LLC | 20,000 | $40,600 | 0.03% |